GINA 2023 — Global Strategy for Asthma Management and Prevention

This guideline has been superseded by a newer recommendation. Check the Knowledge Map or the current topic page for the guideline that replaces it.

First-line therapy for acute severe asthma consists of continuous or frequent short-acting beta-2 agonists combined with ipratropium bromide, early systemic corticosteroids, controlled oxygen targeting SpO2 93-95%, and considering IV magnesium sulfate as an adjunct for severe, life-threatening, or refractory exacerbations.